Taletrectinib (Ibtrozi): A Comprehensive Oncological Drug Monograph

Executive Summary

Taletrectinib, marketed as Ibtrozi, is a next-generation, orally administered, central nervous system (CNS)-active, selective tyrosine kinase inhibitor (TKI) that has emerged as a significant therapeutic advancement for ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).[1] On June 11, 2025, the U.S. Food and Drug Administration (FDA) granted approval for taletrectinib for the treatment of adult patients with locally advanced or metastatic

ROS1+ NSCLC, a decision that applies to both TKI-naïve and previously treated patient populations.[4] This approval is predicated on a robust body of evidence from the pivotal Phase 2 clinical trials, TRUST-I and TRUST-II, which demonstrated high and durable systemic and intracranial response rates.[2]

The clinical profile of taletrectinib is distinguished by several key attributes that address critical unmet needs in the management of ROS1+ NSCLC. The agent exhibits potent activity against the common crizotinib-acquired resistance mutation, ROS1 G2032R, a significant mechanism of treatment failure for first-generation TKIs.[3] Furthermore, taletrectinib was designed for superior penetration of the blood-brain barrier, translating to compelling intracranial efficacy in patients with CNS metastases, a frequent and challenging complication of this disease.[3] This is coupled with a favorable neurological safety profile, which is attributed to its high selectivity for ROS1 over tropomyosin receptor kinase B (TRKB), thereby minimizing the dose-limiting neurological adverse events associated with less selective inhibitors.[1]

Data from a pooled analysis of the TRUST-I and TRUST-II trials underscore its best-in-class potential. In TKI-naïve patients, taletrectinib achieved a confirmed objective response rate (cORR) of 88.8% and a median progression-free survival (PFS) of 45.6 months.[10] In patients previously treated with a ROS1 TKI, it demonstrated a cORR of 55.8% and a median PFS of 9.7 months.[10] These results position taletrectinib as a new standard of care, offering a highly effective and well-tolerated option that has the potential to significantly improve outcomes for patients with

ROS1+ NSCLC.

Introduction to Taletrectinib (Ibtrozi)

Drug Profile and Classification

Taletrectinib, approved under the brand name Ibtrozi, is a small molecule kinase inhibitor developed for precision oncology.[4] It is also identified by the development codes AB-106 and DS-6051b.[12] As a therapeutic agent, taletrectinib is classified as a next-generation, orally bioavailable, central nervous system (CNS)-active tyrosine kinase inhibitor (TKI) with high selectivity for both the ROS1 proto-oncogene and the neurotrophic tyrosine receptor kinase (NTRK) family of proteins.[1] Its primary indication is for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor a

ROS1 gene fusion.[4]

Development and Corporate History

The development of taletrectinib has been characterized by a series of strategic licensing agreements and a significant corporate acquisition, reflecting its perceived high value in the oncology market.

The compound, originally known as DS-6051, was discovered and initially developed by [Daiichi Sankyo Inc.].[13] Subsequently,

[AnHeart Therapeutics], a clinical-stage global biopharmaceutical company, acquired the global development and commercialization rights, advancing the drug under the identifier AB-106.[13] AnHeart strategically established a network of partnerships to maximize the global reach of taletrectinib. In 2021, it entered into an exclusive license agreement with

[Innovent Biologics] for the co-development and commercialization of the drug in Greater China (mainland China, Hong Kong, Macau, and Taiwan).[2] Similar agreements were made with

[Nippon Kayaku] for the Japanese market and [NewG Lab] for Korea.[15]

A transformative event in the drug's history occurred in March 2024, when [Nuvation Bio Inc.] announced its acquisition of AnHeart Therapeutics in an all-stock transaction.[15] This strategic move was designed to transition Nuvation Bio into a late-stage, commercial-ready oncology company, with taletrectinib becoming its lead asset. The acquisition, which was approved by the boards of both companies, positioned Nuvation Bio to finalize the pivotal clinical studies and pursue global regulatory approvals, with the stated goal of becoming a commercial organization by the end of 2025.[2]

Unmet Medical Need in ROS1-Positive NSCLC

ROS1 gene fusions represent a distinct molecular subtype of NSCLC, occurring in approximately 1% to 2% of cases.[16] This subtype is often associated with a unique patient demographic, typically younger individuals with a limited or non-existent history of smoking.[16] While rare,

ROS1-rearranged NSCLC presents significant clinical challenges that underscore the need for advanced therapeutic options.

A primary challenge is the high incidence of CNS metastases. Up to 40% of patients present with brain metastases at initial diagnosis, and the CNS is a common site of disease progression, affecting up to 55% of patients following initial treatment.[5] First-generation ROS1 TKIs, such as crizotinib, exhibit limited penetration of the blood-brain barrier, resulting in suboptimal intracranial disease control.[20]

A second major hurdle is the development of acquired resistance to TKI therapy. Following treatment with first-generation inhibitors, tumors frequently develop secondary resistance mutations within the ROS1 kinase domain. The most common of these is the solvent-front mutation G2032R, which confers resistance to crizotinib and entrectinib, leading to treatment failure.[3]

While next-generation TKIs like entrectinib and repotrectinib were developed to improve CNS activity and overcome some resistance mechanisms, their utility can be limited by off-target neurological adverse events (AEs). These AEs, including dizziness, dysgeusia, and ataxia, are often attributed to the concurrent inhibition of the TRKB protein.[1] Therefore, a significant unmet medical need exists for a next-generation ROS1 TKI that combines potent, durable systemic and intracranial efficacy, activity against key resistance mutations like

G2032R, and a favorable safety profile with minimal neurological toxicity. Taletrectinib was specifically engineered to address this therapeutic gap.[3]

Mechanism of Action and Pharmacology

Primary Targets and Inhibitory Profile

Taletrectinib is a type I TKI, meaning it binds to the ATP-binding pocket of the target kinase in its active conformation. Its primary targets are the ROS1 and NTRK (NTRK1, NTRK2, NTRK3) tyrosine kinases.[3] In cancers driven by

ROS1 gene fusions, the resulting chimeric protein is constitutively active, leading to the persistent activation of downstream signaling pathways critical for cell survival and proliferation, including the PI3K/AKT and MAPK/ERK pathways. By binding to the ATP-binding site of the ROS1 kinase domain, taletrectinib potently inhibits its phosphorylation activity, thereby blocking these oncogenic signals and inducing tumor cell death.[8]

Activity Against Acquired Resistance Mutations

A defining feature of taletrectinib is its robust activity against mutations that confer resistance to earlier-generation ROS1 inhibitors.

Efficacy Against the G2032R Solvent-Front Mutation

The ROS1 G2032R mutation is the most common on-target resistance mechanism that emerges in patients treated with crizotinib and is also a liability for entrectinib.[3] This mutation sterically hinders the binding of these first-generation inhibitors. Taletrectinib was rationally designed to overcome this steric hindrance, maintaining potent inhibitory activity against the

G2032R-mutant ROS1 protein.[3] This preclinical potency translates directly to clinical efficacy. In a pooled analysis of the TRUST trials, taletrectinib demonstrated a cORR of 61.5% (8 out of 13 evaluable patients) in the cohort of patients whose tumors harbored a baseline

G2032R mutation acquired after prior TKI therapy.[7] This confirms its role as an effective therapeutic option for patients who have progressed on crizotinib or entrectinib due to this specific resistance mechanism.

Emerging Resistance: The ROS1 L2086F Mutation and Future Therapeutic Sequencing

While taletrectinib effectively targets the G2032R mutation, the evolution of cancer under therapeutic pressure inevitably leads to new forms of resistance. The identification of the [ROS1 L2086F mutation] as an on-target resistance mechanism to taletrectinib and other type I TKIs represents a critical insight into the future management of ROS1+ NSCLC.[24]

The L2086F mutation, located in the catalytic spine 6 (CS6) of the kinase domain, appears to disrupt the binding of type I TKIs, including crizotinib, entrectinib, lorlatinib, repotrectinib, and taletrectinib.[26] This finding establishes a key limitation of the current generation of ROS1 inhibitors and underscores the necessity of ongoing genomic surveillance of tumors upon disease progression.

The discovery of this mutation, however, also illuminates a rational path forward for sequential therapy. Preclinical and clinical evidence has shown that certain type II TKIs, which bind to the kinase in its inactive (DFG-out) conformation, retain activity against the L2086F mutation. Specifically, [cabozantinib] and [merestinib] have demonstrated preclinical efficacy, and there are now clinical case reports of patients with the ROS1 L2086F mutation responding to cabozantinib after progressing on taletrectinib or lorlatinib.[26] Additionally, the type I FLT3 inhibitor

[gilteritinib] has also shown preclinical activity against the L2086F mutant.[26]

This understanding of sequential resistance mechanisms is of profound clinical importance. It transforms the treatment paradigm from a series of independent therapeutic choices into a more predictable, evidence-based sequence. For a patient with newly diagnosed ROS1+ NSCLC, a potential treatment trajectory could be:

1. First-line treatment with a next-generation TKI like taletrectinib to maximize initial response duration and intracranial control.
2. Upon progression, liquid or tissue biopsy to identify the resistance mechanism.
3. If an L2086F mutation is detected, a switch to a type II TKI such as cabozantinib would be the rational next step. This sequential strategy informs clinical decision-making, guides the development of next-generation companion diagnostics that must include testing for L2086F, and provides a framework for future clinical trials designed to optimize the treatment sequence for patients with ROS1-rearranged NSCLC.

Central Nervous System (CNS) Penetration and Selectivity

The superior clinical profile of taletrectinib is significantly defined by its dual properties of high CNS penetration and its kinase selectivity, which together provide a strong therapeutic window for treating intracranial disease.

CNS metastases are a major driver of morbidity and mortality in ROS1+ NSCLC.[8] While second-generation TKIs like entrectinib and repotrectinib were developed to be CNS-active, their clinical utility is often hampered by neurological adverse events such as dizziness, dysgeusia, paresthesia, and ataxia.[3] These toxicities are largely attributed to the off-target inhibition of TRKB, a neurotrophic receptor kinase crucial for neuronal function.

Taletrectinib was engineered to circumvent this liability. Preclinical kinase assays demonstrated that taletrectinib is 11- to 20-fold more selective for ROS1 than for TRKB.[3] This enhanced selectivity is hypothesized to be the primary reason for its more favorable neurological safety profile observed in clinical trials. In parallel, preclinical pharmacokinetic studies in rats demonstrated superior CNS penetration and sustained brain concentrations for taletrectinib compared to repotrectinib.[3]

This optimized molecular design translates directly into a compelling clinical benefit-risk profile. The pooled analysis of the TRUST trials showed a high intracranial cORR of 76.5% in TKI-naïve patients and 65.6% in TKI-pretreated patients.[10] These robust efficacy data are accompanied by a low incidence of neurologic TEAEs, which were mostly Grade 1 and transient. Dizziness was reported in approximately 21-23% of patients and dysgeusia in 10-15%.[7] This combination of potent intracranial activity and improved neurological tolerability positions taletrectinib as a highly attractive option, particularly for first-line treatment, where long-term quality of life is a major consideration.

Pharmacokinetics and Metabolism

Taletrectinib is administered orally as a capsule and exhibits predictable pharmacokinetic properties that support a convenient dosing schedule.[12]

• [Absorption, Distribution, and Elimination:] The drug is orally bioavailable and demonstrates dose-dependent increases in peak concentration (Cmax​) and exposure (AUC).[24] It has a long terminal half-life of approximately 66 hours, which allows for effective once-daily dosing.[5] Taletrectinib achieves broad tissue distribution, which includes effective penetration across the blood-brain barrier.[3]
• [Food Effect:] The presence of food affects the absorption of taletrectinib. A study showed that a low-fat meal increased the AUC by approximately 23%.[24] To ensure consistent exposure and minimize variability, the FDA-approved label recommends that taletrectinib be administered on an empty stomach, defined as no food intake for at least 2 hours before and 2 hours after taking the dose.[4] Patients should also avoid grapefruit and grapefruit juice, as they are known to inhibit CYP3A enzymes and could increase taletrectinib concentrations.[29]
• [Metabolism and Excretion:] In vitro studies using human, rat, and dog liver microsomes have elucidated the metabolic pathways of taletrectinib. The drug undergoes extensive Phase I metabolism, primarily through [N-dealkylation], [O-dealkylation], [oxidative deamination], and [oxygenation].[31] A total of 10 metabolites were identified across species, with seven observed in human liver microsomes. The most abundant human metabolite was identified as M5, a lactam derivative formed via oxygenation. Other key metabolites include M1 (N-dealkylation product), M8 (O-dealkylation product), and M10 (taletrectinib ketone, an oxidative deamination product). M10 can be further reduced to M9 (taletrectinib alcohol). Phase II metabolism involves [glucuronidation] of the alcohol derivative M9, though this was observed in dogs but not in human microsomes.[31]
• [Drug-Drug Interactions:] Taletrectinib is metabolized by cytochrome P450 3A (CYP3A) enzymes. Consequently, its plasma concentrations can be significantly altered by co-administration with strong or moderate CYP3A inhibitors (which would increase exposure and risk of toxicity) or inducers (which would decrease exposure and risk of reduced efficacy). Therefore, concomitant use of these agents should be avoided.[29] Additionally, gastric acid-reducing agents like proton pump inhibitors (PPIs) and H2 receptor antagonists can affect taletrectinib's absorption and should also be avoided. If necessary, a locally acting antacid may be used if administered at least 2 hours before or 2 hours after the taletrectinib dose.[29]

Clinical Development and Efficacy

The clinical development program for taletrectinib has been robust, culminating in regulatory approvals based on compelling efficacy data from two pivotal Phase 2 trials.

Overview of Pivotal Clinical Trials

The foundation of taletrectinib's approval rests on two multicenter, single-arm, open-label Phase 2 studies:

• [TRUST-I (NCT04395677):] A regional study conducted primarily in China.[4]
• [TRUST-II (NCT04919811):] A global study enrolling patients in North America, Europe, and Asia.[4]

Both trials evaluated the efficacy and safety of taletrectinib administered at a dose of 600 mg once daily. The studies included distinct cohorts of patients with advanced or metastatic ROS1-positive NSCLC: those who were TKI-naïve and those who had been pretreated with one prior ROS1 TKI (crizotinib in TRUST-I; crizotinib or entrectinib in TRUST-II).[4] The primary endpoint in both registrational cohorts was the confirmed objective response rate (cORR) as assessed by a blinded independent review committee (IRC) according to RECIST v1.1 criteria.[34]

Efficacy in TKI-Naïve ROS1-Positive NSCLC

A pooled analysis of the TKI-naïve cohorts from TRUST-I and TRUST-II, comprising 160 patients, demonstrated remarkable efficacy, establishing taletrectinib as a potent first-line treatment option.[10]

• [Objective Response Rate (ORR):] The pooled cORR was [88.8%] (95% CI, 82.8%-93.2%). This included 8 patients (5.0%) with a complete response (CR) and 134 patients (83.8%) with a partial response (PR).[10] The high rate of tumor shrinkage was consistent across both individual trials, with a cORR of 90.6% in TRUST-I and 85.2% in TRUST-II.[7]
• [Duration of Response (DOR):] Responses were exceptionally durable. The median DOR for the pooled population was [44.2 months] (95% CI, 30.4-NR).[10] At 24 months, an estimated 78.6% of responders remained in response.[40]
• [Progression-Free Survival (PFS):] The profound and durable responses translated into a significant extension of PFS. The median PFS for the pooled TKI-naïve population was [45.6 months] (95% CI, 29.0-NR).[10] The estimated 24-month PFS rate was 70.5%.[40]
• [Overall Survival (OS):] At the time of the analysis, the median OS had not been reached, indicating a strong survival benefit. The estimated 12-month OS rate was 77.5%.[11]

Efficacy in TKI-Pretreated ROS1-Positive NSCLC

Taletrectinib also demonstrated clinically meaningful activity in 113 patients who had progressed on a prior ROS1 TKI, a setting with significant unmet need.[10]

• [Objective Response Rate (ORR):] The pooled cORR was [55.8%] (95% CI, 46.1%-65.1%).[10] The ORR was 51.5% in the crizotinib-pretreated cohort of TRUST-I and 61.7% in the pretreated cohort of TRUST-II (which included patients post-crizotinib or entrectinib).[7]
• [Duration of Response (DOR):] The median DOR in the pooled pretreated population was [16.6 months] (95% CI, 10.6-27.3).[10]
• [Progression-Free Survival (PFS):] The median PFS was [9.7 months] (95% CI, 6.8-19.7).[10]

These data confirm that taletrectinib provides a durable and effective second-line option for patients with ROS1+ NSCLC after failure of a first-generation TKI.

Intracranial Efficacy

The performance of taletrectinib in patients with CNS metastases is a cornerstone of its clinical value. The pooled analysis provided robust evidence of its intracranial activity.

• [TKI-Naïve Patients:] In the 17 TKI-naïve patients with measurable baseline brain metastases, the intracranial cORR was [76.5%] (95% CI, 50.1-93.2). The median intracranial DOR was [14.7 months] (95% CI, 4.2-30.2).[10]
• [TKI-Pretreated Patients:] In the 32 TKI-pretreated patients with measurable baseline brain metastases, the intracranial cORR was [65.6%] (95% CI, 46.8-81.4). The median intracranial DOR was [11.9 months] (95% CI, 6.9-23.5).[10]

The following table summarizes the key efficacy outcomes from the pooled analysis of the TRUST-I and TRUST-II trials.

Efficacy Endpoint	TKI-Naïve (n=160)	TKI-Pretreated (n=113)
Systemic Efficacy
cORR (95% CI)	88.8% (82.8, 93.2)	55.8% (46.1, 65.1)
DCR (95% CI)	95.0% (90.4, 97.8)	87.6% (80.1, 93.1)
Median DOR, months (95% CI)	44.2 (30.4, NR)	16.6 (10.6, 27.3)
Median PFS, months (95% CI)	45.6 (29.0, NR)	9.7 (6.8, 19.7)
Intracranial Efficacy
IC-cORR (95% CI)	76.5% (50.1, 93.2)	65.6% (46.8, 81.4)
IC-DCR (95% CI)	88.2% (63.6, 98.5)	93.8% (79.2, 99.2)
Median IC-DOR, months (95% CI)	14.7 (4.2, 30.2)	11.9 (6.9, 23.5)
Data sourced from a pooled analysis of TRUST-I and TRUST-II trials.10 cORR: confirmed objective response rate; DCR: disease control rate; DOR: duration of response; PFS: progression-free survival; IC: intracranial; NR: not reached.

Activity in NTRK Fusion-Positive Solid Tumors

In addition to its potent ROS1 inhibition, taletrectinib is a pan-NTRK inhibitor, creating the potential for a tumor-agnostic indication similar to larotrectinib and entrectinib.[12] An ongoing Phase 2 basket trial,

[NCT04617054], was initiated to evaluate the efficacy of taletrectinib in patients with various solid tumors harboring NTRK1/2/3 gene fusions.[9]

While comprehensive results from this basket trial are pending, early data have been encouraging. The initial US Phase 1 study reported a durable confirmed partial response lasting over 27 months in a patient with a TPM3−NTRK1 fusion-positive differentiated thyroid cancer.[24] The successful development pathways of other TRK inhibitors provide a clear precedent for this indication, and the full data from NCT04617054 will be critical in determining taletrectinib's potential for a tumor-agnostic label expansion.

Safety and Tolerability Profile

The safety of taletrectinib has been evaluated in a pooled population of 352 patients from its clinical development program, demonstrating a manageable and predictable safety profile.[9]

Comprehensive Adverse Event Analysis

The majority of treatment-emergent adverse events (TEAEs) associated with taletrectinib were Grade 1 or 2 in severity, transient, and manageable with supportive care or dose modifications.[8]

• [Most Common Adverse Reactions:] The most frequently reported TEAEs (≥20% incidence) in the pooled safety population were primarily gastrointestinal and constitutional. These included diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).[5]
• [Common Laboratory Abnormalities:] The most common laboratory abnormalities were elevations in liver transaminases. Increased aspartate aminotransferase (AST) was observed in 72-88% of patients, and increased alanine aminotransferase (ALT) was seen in 68-85% of patients. The vast majority of these elevations were Grade 1-2.[5]
• [Grade 3 or Higher Adverse Events:] Grade 3 or 4 TEAEs occurred in approximately 51-54% of patients.[25] The most common Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%) and increased AST (10%).[5]
• [Dose Modifications and Discontinuations:] Dose interruptions due to TEAEs were necessary in approximately 40% of patients, and dose reductions occurred in about 19-29% of patients.[7] Importantly, the rate of permanent discontinuation due to TEAEs was low, at approximately 6.5-7%.[9]

The following table summarizes the most common adverse reactions from the pooled safety analysis of the TRUST-I and TRUST-II trials.

Adverse Reaction	IBTROZI (N=337) All Grades (%)	IBTROZI (N=337) Grade 3 or 4 (%)
Gastrointestinal Disorders
Diarrhea	64	2.1
Nausea	47	0.9
Vomiting	43	0.9
Constipation	21	0
Nervous System Disorders
Dizziness	22	0.3
Skin and Subcutaneous Tissue
Rash	22	1.8
General Disorders
Fatigue	20	0.9
Cardiac Disorders
Electrocardiogram QT prolonged	19	3.6
Metabolism and Nutritional
Decreased appetite	16	0.3
Data from IBTROZI™ (taletrectinib) Prescribing Information.29

Warnings and Precautions

The FDA-approved prescribing information for Ibtrozi includes several important warnings and precautions that require careful monitoring and management by clinicians.[4]

• [Hepatotoxicity:] Taletrectinib can cause hepatotoxicity, including drug-induced liver injury and, rarely, fatal events (0.6%). The median time to onset of transaminase elevation is approximately 15 days. Liver function tests (ALT, AST, and bilirubin) should be monitored every 2 weeks during the first 2 months of treatment and monthly thereafter. Dose interruption, reduction, or permanent discontinuation may be required based on the severity of hepatotoxicity.
• [Interstitial Lung Disease (ILD)/Pneumonitis:] Severe, life-threatening, or fatal ILD/pneumonitis can occur. In clinical trials, the incidence was 2.3%, with 1.1% being Grade 3 or 4. Patients should be monitored for new or worsening pulmonary symptoms, and Ibtrozi should be withheld immediately if ILD/pneumonitis is suspected.
• [QTc Interval Prolongation:] Taletrectinib can cause concentration-dependent QTc interval prolongation, which may increase the risk of ventricular tachyarrhythmias. ECGs and electrolytes should be monitored at baseline and periodically during treatment. The risk is increased if taken with food, reinforcing the need for administration on an empty stomach. Concomitant use of other drugs known to prolong the QTc interval should be avoided.
• [Hyperuricemia:] The drug can cause elevations in serum uric acid. Levels should be monitored at baseline and periodically, with urate-lowering medications initiated as clinically indicated.
• [Myalgia with Creatine Phosphokinase (CPK) Elevation:] Myalgia, with or without CPK elevation, can occur. Serum CPK levels should be monitored every 2 weeks for the first month and as clinically indicated thereafter, especially in patients reporting muscle pain.
• [Skeletal Fractures:] An increased risk of skeletal fractures has been associated with ROS1 inhibitors. Patients presenting with signs or symptoms such as pain or changes in mobility should be promptly evaluated.
• [Photosensitivity:] Taletrectinib can cause photosensitivity. Patients should be advised to minimize sun exposure and use broad-spectrum sunscreen during treatment and for at least 5 days after discontinuation.
• [Embryo-Fetal Toxicity:] Based on its mechanism of action and findings in animals, taletrectinib can cause fetal harm. Females of reproductive potential and male patients with female partners of reproductive potential must use effective contraception during treatment and for a specified period after the final dose.

Dose and Administration

The recommended dosage of Ibtrozi is [600 mg taken orally once daily].[4] The capsules should be swallowed whole and taken on an empty stomach (no food for at least 2 hours before and 2 hours after administration).[14] Treatment should continue until disease progression or unacceptable toxicity occurs.

For management of adverse reactions, the following dose reduction schedule is recommended:

• First dose reduction: 400 mg once daily
• Second dose reduction: 200 mg once daily

If a patient is unable to tolerate the 200 mg daily dose, the drug should be permanently discontinued.[14]

Regulatory and Commercial Landscape

Global Regulatory Status

Taletrectinib has achieved significant regulatory milestones in major global markets, reflecting the strength of its clinical data and the recognized unmet need in ROS1+ NSCLC.

• [United States (FDA):] On [June 11, 2025], the FDA granted full approval to taletrectinib (Ibtrozi) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC.[4] The approval is line-agnostic, meaning it is for both TKI-naïve and previously treated patients. The FDA had previously granted the application [Priority Review], as well as [Breakthrough Therapy Designation] and [Orphan Drug Designation], underscoring the drug's potential to provide a substantial improvement over available therapies.[4]
• [China (NMPA):] China's National Medical Products Administration (NMPA) approved taletrectinib (Dovbleron) in [January 2025] for adult patients with locally advanced or metastatic ROS1+ NSCLC.[16] This followed the granting of Priority Review and Breakthrough Therapy Designations.[17] The commercialization in Greater China is handled by Innovent Biologics.[16]
• [Japan (PMDA):] A Marketing Authorization Application (MAA) was submitted to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in [March 2025] by Nuvation Bio's partner, Nippon Kayaku.[13]
• [Other Regions:] Regulatory submissions are also underway or planned in other regions, including Europe.[16]

Commercialization and Market Access Strategy

Nuvation Bio has outlined a clear and well-funded strategy to support the commercial launch and market access for Ibtrozi.

• [U.S. Commercial Launch:] Following the FDA approval, Nuvation Bio is proceeding with a U.S. commercial launch in mid-2025.[58] The launch is fully supported by a strategic, non-dilutive financing agreement of up to $250 million from Sagard Healthcare Partners, which includes $150 million in royalty interest financing and up to $100 million in debt, contingent on the approval and first commercial sale.[58] This financial structure is intended to fund the launch and ongoing pipeline development without requiring additional equity fundraising, providing a clear path to potential profitability.[59]
• [Pricing and Market Positioning:] The wholesale acquisition cost (WAC) for Ibtrozi in the U.S. has been set at approximately [$29,500 to $29,844 per month].[64] This price is positioned competitively relative to other branded oral oncology agents, including rival TKIs like repotrectinib (Augtyro), which is priced at approximately $160,000 per year.[67] Analysts project peak annual sales for taletrectinib to reach between $640 million and over $1.2 billion, driven by its potential to become the dominant first-line therapy, its durable responses leading to long treatment durations, and global expansion.[67]
• [Patient Support and Market Development:] To facilitate patient access, Nuvation Bio has launched [NuvationConnect], a comprehensive patient support program. This program provides financial assistance, access to educational resources, and personalized support for eligible patients prescribed Ibtrozi.[5] The company is also focused on physician education to promote biomarker testing and ensure the timely identification of the ROS1+ patient population, which is currently underdiagnosed.[67] The recent shift in NCCN guidelines to contraindicate immunotherapy in favor of immediate TKI use for ROS1+ NSCLC is expected to serve as a significant tailwind for Ibtrozi's adoption.[67]

Comparative Analysis and Future Directions

Positioning Against Competing ROS1 TKIs

The therapeutic landscape for ROS1-positive NSCLC has evolved rapidly, from first-generation inhibitors to more potent and CNS-active next-generation agents. Taletrectinib enters this market with a clinical profile that appears highly competitive, particularly against the existing standards of care.

• [Versus Crizotinib:] Crizotinib, the first-generation TKI, established the principle of ROS1 inhibition but is hampered by poor CNS penetration and a relatively short median PFS of approximately 10-19 months in the first-line setting.[21] Taletrectinib's median PFS of 45.6 months in TKI-naïve patients and its robust intracranial ORR of 76.5% represent a substantial improvement in both durability and CNS disease control.[10]
• [Versus Entrectinib:] Entrectinib was designed for CNS activity but shows limited efficacy against the G2032R resistance mutation and has demonstrated only modest activity in patients with CNS-only progression after crizotinib (ORR of 11%).[20] A matching-adjusted indirect comparison (MAIC) analysis strongly favored taletrectinib, which showed a significantly higher ORR (87.6% vs. 67.1%) and a 58% reduction in the risk of disease progression compared to entrectinib in TKI-naïve patients.[105]
• [Versus Repotrectinib:] Repotrectinib (Augtyro) is taletrectinib's most direct next-generation competitor, also demonstrating potent systemic and intracranial activity, including against the G2032R mutation.[22] The key differentiator lies in the safety profile. Repotrectinib is associated with a high incidence of neurologic AEs, including dizziness (58-65%) and dysgeusia (50%), due to its off-target TRK inhibition.[22] In contrast, taletrectinib's selectivity for ROS1 over TRKB results in a much lower incidence of these AEs (dizziness ~22%, dysgeusia ~15%), offering a significant advantage in terms of long-term tolerability and patient quality of life.[9] This superior safety profile, combined with comparable or superior efficacy metrics, strongly positions taletrectinib as a preferred first-line agent.

The following table provides a comparative summary of key efficacy and safety data for approved ROS1 TKIs.

Feature	Taletrectinib (Ibtrozi)	Repotrectinib (Augtyro)	Entrectinib (Rozlytrek)	Crizotinib (Xalkori)
TKI-Naïve Systemic Efficacy
ORR	88.8%	79%	68%	72%
Median PFS	45.6 months	35.7 months	15.7 months	19.4 months
Median DOR	44.2 months	34.1 months	20.5 months	24.7 months
TKI-Naïve Intracranial Efficacy
IC-ORR	76.5%	89%	80%	18% (retrospective)
Median IC-DOR	14.7 months	Range: 1.9-14.8+ months	12.9 months	26.4 weeks (retrospective)
Key Safety Issues (% Grade ≥3)
Dizziness	0.3%	2.8%	N/A	N/A
Hepatotoxicity (ALT/AST)	13% / 10%	3.3% / 2.9%	N/A	14%
Data compiled from sources.10 Data are from different trials and are not from direct head-to-head comparisons.

Future Research and Directions

The approval of taletrectinib marks a significant milestone, but further research is necessary to fully define its role and optimize its use.

• [Head-to-Head Confirmation:] An ongoing Phase 3 trial (NCT06564324) is comparing taletrectinib directly against crizotinib in TKI-naïve patients.[8] The results of this study will provide definitive Level 1 evidence to solidify taletrectinib's position as the standard of care in the first-line setting.
• [Early-Stage Disease:] As with many successful targeted therapies in the metastatic setting, future investigations will likely explore the utility of taletrectinib in the adjuvant or neoadjuvant settings for patients with earlier-stage, resectable ROS1+ NSCLC.[1]
• [Combination Strategies:] Given the eventual development of resistance, exploring rational combination therapies is a logical next step. This could involve combining taletrectinib with chemotherapy, other targeted agents to overcome bypass track resistance, or potentially immunotherapy in select patient subgroups.[30]
• [Expanding Indications:] The ongoing basket trial in NTRK fusion-positive solid tumors (NCT04617054) holds the potential to expand taletrectinib's approval to a tumor-agnostic indication, significantly broadening its clinical utility.[42]

Conclusion

Taletrectinib (Ibtrozi) has established itself as a formidable agent in the treatment of ROS1-positive non-small cell lung cancer. Its recent FDA approval is a testament to a well-executed clinical development program that yielded impressive results in both TKI-naïve and pretreated patient populations. The drug's high and durable systemic response rates, coupled with its robust intracranial activity, directly address the primary challenges of managing this disease.

The molecular design of taletrectinib, which confers both potent activity against the common G2032R resistance mutation and a favorable neurological safety profile due to its selectivity over TRKB, provides a clear clinical advantage over existing therapies. This positions Ibtrozi as a potential new global standard of care, particularly in the first-line setting where long-term efficacy and tolerability are paramount. While the emergence of new resistance mutations such as L2086F will require continued vigilance and research, the identification of active subsequent therapies provides a rational framework for sequential treatment. Backed by a strong commercialization strategy, taletrectinib is poised to make a profound and positive impact on the lives of patients with this rare and aggressive form of lung cancer.

Works cited

1. Taletrectinib: A New Advance in ROS1-Mutant NSCLC - Targeted Oncology, accessed June 16, 2025, https://www.targetedonc.com/view/taletrectinib-a-new-advance-in-ros1-mutant-nsclc
2. Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2024/Nuvation-Bio-Announces-Data-from-Pivotal-Phase-2-TRUST-I-Study-of-its-Investigational-ROS1-Inhibitor-Taletrectinib-are-Published-in-the-Journal-of-Clinical-Oncology-and-Reported-at-2024-ASCO-Annual-Meeting/default.aspx
3. Taletrectinib for the treatment of ROS-1 positive non-small cell lung ..., accessed June 16, 2025, https://www.tandfonline.com/doi/full/10.1080/13543784.2024.2305131
4. FDA approves taletrectinib for ROS1-positive non-small cell lung cancer, accessed June 16, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-taletrectinib-ros1-positive-non-small-cell-lung-cancer
5. U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2025/U-S--Food-and-Drug-Administration-Approves-Nuvation-Bios-IBTROZI-taletrectinib-a-Next-Generation-Oral-Treatment-for-Advanced-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx
6. AnHeart Therapeutics Receives FDA Breakthrough Therapy Designation for Taletrectinib in ROS1-Positive Non-Small Cell Lung Cancer - BioSpace, accessed June 16, 2025, https://www.biospace.com/anheart-therapeutics-receives-fda-breakthrough-therapy-designation-for-taletrectinib-in-ros1-positive-non-small-cell-lung-cancer
7. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ ..., accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/38822758/
8. FDA Approves Taletrectinib for ROS1-Positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://www.targetedonc.com/view/fda-approves-taletrectinib-for-ros1-positive-non-small-cell-lung-cancer
9. Efficacy of Taletrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC | ESMO, accessed June 16, 2025, https://www.esmo.org/oncology-news/efficacy-of-taletrectinib-in-patients-with-advanced-ros1-fusion-positive-nsclc
10. Pooled TRUST-I and TRUST-II Data Affirm Taletrectinib Benefits for Advanced ROS1+ NSCLC - OncLive, accessed June 16, 2025, https://www.onclive.com/view/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc
11. Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC, accessed June 16, 2025, https://www.cancernetwork.com/view/taletrectinib-yields-durable-responses-prolonged-pfs-in-ros1-nsclc
12. Taletrectinib: A Promising Treatment for Certain Types of Cancer - Clinical trials, accessed June 16, 2025, https://clinicaltrials.eu/inn/taletrectinib/
13. AnHeart Therapeutics - Taletrectinib - AdisInsight - Springer, accessed June 16, 2025, https://adisinsight.springer.com/drugs/800041538
14. Ibtrozi (taletrectinib) dosing, indications, interactions, adverse effects, and more - Medscape, accessed June 16, 2025, https://reference.medscape.com/drug/ibtrozi-taletrectinib-4000505
15. Nuvation Bio to Acquire AnHeart Therapeutics in ... - Nuvation Bio Inc., accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2024/Nuvation-Bio-to-Acquire-AnHeart-Therapeutics-in-All-Stock-Transaction/default.aspx
16. Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Receives-Approval-from-Chinas-National-Medical-Products-Administration-for-Taletrectinib-for-Patients-with-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx
17. Press Release, accessed June 16, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=434
18. Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://investors.guardanthealth.com/press-releases/press-releases/2023/Guardant-Health-and-AnHeart-Therapeutics-Announce-Collaboration-to-Develop-Guardant360-CDx-and-Guardant360-TissueNext-as-Companion-Diagnostics-for-Taletrectinib-in-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx
19. Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration - PR Newswire, accessed June 16, 2025, https://www.prnewswire.com/news-releases/innovent-announces-second-new-drug-application-of-dovbleron--taletrectinib-adipate-capsule-ros1-inhibitor-was-approved-by-chinas-national-medical-products-administration-302341276.html
20. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9160474/
21. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8127383/
22. Durable Activity of Repotrectinib in Patients with ROS1 Fusion ..., accessed June 16, 2025, https://www.esmo.org/oncology-news/durable-activity-of-repotrectinib-in-patients-with-ros1-fusion-positive-nsclc-regardless-of-previous-treatment-with-a-ros1-tki
23. A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients with ROS1-positive NSCLC | ESMO, accessed June 16, 2025, https://www.esmo.org/oncology-news/a-favourable-benefit-risk-profile-for-taletrectinib-in-tki-nayive-and-crizotinib-pretreated-patients-with-ros1-positive-nsclc
24. U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB ..., accessed June 16, 2025, https://aacrjournals.org/clincancerres/article/26/18/4785/9510/U-S-Phase-I-First-in-human-Study-of-Taletrectinib
25. Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST | Journal of Clinical Oncology, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO-25-00275
26. TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers - bioRxiv, accessed June 16, 2025, https://www.biorxiv.org/content/10.1101/2024.01.16.575901v1.full.pdf
27. US Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK In - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/clincancerres/article-pdf/26/18/4785/2061029/4785.pdf
28. L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case Report - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11293496/
29. Reference ID: 5606454 - accessdata.fda.gov, accessed June 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219713s000lbl.pdf
30. Ibtrozi: Nuvation Bio's Breakthrough in ROS1-Positive Lung Cancer and the Path to Market Dominance - AInvest, accessed June 16, 2025, https://www.ainvest.com/news/ibtrozi-nuvation-bio-breakthrough-ros1-positive-lung-cancer-path-market-dominance-2506/
31. High‐resolution mass spectrometry‐based approach for ... - Sci-Hub, accessed June 16, 2025, https://sci-hub.se/downloads/2021-05-14//73/ye2021.pdf
32. Ibtrozi taletrectinib for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer - JADPRO, accessed June 16, 2025, https://jadpro.com/education/fda-focus/2025/ibtrozi-taletrectinib-for-adults-with-locally-advanced-or-metastatic-ros1-positive-non-small-cell-lung-cancer/
33. FDA Approves Taletrectinib in ROS1+ NSCLC - CancerNetwork, accessed June 16, 2025, https://www.cancernetwork.com/view/fda-approves-taletrectinib-in-ros1-nsclc
34. Phase II Study of Taletrectinib Shows Durable Overall Response and Favorable Safety in Patients with ROS1+ Non-Small Cell Lung Cancer | IASLC, accessed June 16, 2025, https://www.iaslc.org/iaslc-news/press-release/phase-ii-study-taletrectinib-shows-durable-overall-response-and-favorable
35. TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors. | Journal of Clinical Oncology - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.TPS8601
36. Efficacy and safety of taletrectinib in patients with advanced or metastatic ROS1+ non–small cell lung cancer: The phase 2 TRUST-I study. - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.8520
37. Combined Efficacy and Safety Data From 2 Phase 2 Trials of Taletrectinib in Patients Diagnosed With Advanced or Metastatic ROS1-Positive NSCLC - Conference Correspondent, accessed June 16, 2025, https://conference-correspondent.com/highlights/esmo/esmo-2024-wrap-up/combined-efficacy-and-safety-data-from-2-phase-2-trials-of-taletrectinib-in-patients-diagnosed-with-advanced-or-metastatic-ros1-positive-nsclc
38. Taletrectinib Yields Durable Responses in TKI Naive and Crizotinib Pretreated ROS1+ NSCLC - OncLive, accessed June 16, 2025, https://www.onclive.com/view/taletrectinib-yields-durable-responses-in-tki-naive-and-crizotinib-pretreated-ros1-nsclc
39. Taletrectinib Shows Consistent Efficacy, Safety in ROS1+ NSCLC Independent of Prior TKI Exposure - OncLive, accessed June 16, 2025, https://www.onclive.com/view/taletrectinib-shows-consistent-efficacy-safety-in-ros1-nsclc-independent-of-prior-tki-exposure
40. Taletrectinib Gains Chinese Approval for Advanced ROS1-Positive NSCLC, accessed June 16, 2025, https://www.cancernetwork.com/view/taletrectinib-gains-chinese-approval-for-advanced-ros1-positive-nsclc
41. Innovent Announces Taletrectinib（ROS1 Inhibitor）Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting - BioSpace, accessed June 16, 2025, https://www.biospace.com/innovent-announces-taletrectinib-ros1-inhibitor-updated-data-from-pivotal-phase-2-trust-i-study-of-are-published-in-the-jco-and-orally-presentedat-2024-asco-annual-meeting
42. Press Release, accessed June 16, 2025, https://www.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=287
43. Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting - BioSpace, accessed June 16, 2025, https://www.biospace.com/innovent-and-anheart-release-preliminary-results-from-the-phase-ii-trust-trial-of-taletrectinib-in-ros1-fusion-positive-nsclc-at-the-asco-2021-annual-meeting
44. Taletrectinib For NTRK Fusion-Positive Solid Tumors Now Being Dosed in a Clinical Trial, accessed June 16, 2025, https://www.targetedonc.com/view/taletrectinib-for-ntrk-fusion-positive-solid-tumors-now-being-dosed-in-a-clinical-trial
45. TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors. | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/361132708_TRUST-II_A_global_phase_II_study_for_taletrectinib_in_ROS1_fusion-positive_lung_cancer_and_other_solid_tumors
46. TRK Inhibitor Activity and Resistance in TRK Fusion-Positive Cancers in Adults - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9133157/
47. Comparable efficacy and safety of taletrectinib for advanced ROS1+ non–small cell lung cancer across pivotal studies and between races and world regions. - ASCO, accessed June 16, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT503076
48. Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting | Morningstar, accessed June 16, 2025, https://www.morningstar.com/news/business-wire/20250521881222/nuvation-bio-to-present-new-data-from-pivotal-clinical-studies-of-taletrectinib-in-advanced-ros1-positive-non-small-cell-lung-cancer-at-asco-2025-annual-meeting
49. Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1+ Non-Small Cell Lung Cancer: The Phase 2 TRUST-I Study - nuvation bio, inc., accessed June 16, 2025, https://nuvationbio.com/wp-content/uploads/2024/05/ASCO-2024-Taletrectinib-C203-Rapid-Oral_FINAL-05.24.2024.pdf
50. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9365368/
51. Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8474193/
52. Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/pdf/10.1200/JCO-25-00275
53. TRUST-II: A global phase II study for taletrectinib in ROS1 fusion–positive lung cancer and other solid tumors. - ASCO, accessed June 16, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT366118
54. Impact of EGFR mutation and types of treatment on the longitudinal recurrence risk in patients with completely resected non-small cell lung cancer - ASCO Annual Meeting, accessed June 16, 2025, https://meetings.asco.org/abstracts-presentations/search?q=Shunichi%20Sugawara%20
55. Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting - PR Newswire, accessed June 16, 2025, https://www.prnewswire.com/news-releases/innovent-and-anheart-announce-interim-data-from-phase-2-trial-of-taletrectinib-in-ros1-positive-nsclc-at-the-csco-2021-annual-meeting-301385147.html
56. U.S. FDA Approves Nuvation Bio's Ibtrozi - Contract Pharma, accessed June 16, 2025, https://www.contractpharma.com/breaking-news/u-s-fda-approves-nuvation-bios-ibtrozi/
57. Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Announces-Expanded-Access-Program-in-the-U.S.-for-Taletrectinib-in-Advanced-ROS1-positive-Non-Small-Cell-Lung-Cancer/default.aspx
58. EX-99.1 - SEC.gov, accessed June 16, 2025, https://www.sec.gov/Archives/edgar/data/1811063/000119312525114908/d905090dex991.htm
59. Nuvation Bio: Riding the Winds of Regulatory Approval and Commercial Readiness, accessed June 16, 2025, https://www.ainvest.com/news/nuvation-bio-riding-winds-regulatory-approval-commercial-readiness-2505/
60. Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Reports-First-Quarter-2025-Financial-Results-and-Provides-Business-Update/default.aspx
61. Nuvation Bio raises $250m for taletrectinib launch - Patsnap Synapse, accessed June 16, 2025, https://synapse.patsnap.com/article/nuvation-bio-raises-250m-for-taletrectinib-launch
62. Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners, accessed June 16, 2025, https://investors.nuvationbio.com/news/news-details/2025/Nuvation-Bio-Secures-Up-to-250-Million-in-Non-Dilutive-Financings-from-Sagard-Healthcare-Partners/default.aspx
63. Nuvation Bio secures $250m for taletrectinib commercialisation, accessed June 16, 2025, https://www.pharmaceutical-technology.com/news/nuvation-bio-taletrectinib/
64. Nuvation Bio stock holds steady as FDA approves lung cancer drug - Investing.com, accessed June 16, 2025, https://www.investing.com/news/analyst-ratings/nuvation-bio-stock-holds-steady-as-fda-approves-lung-cancer-drug-93CH-4094811
65. Nuvation Bio price target maintained at $6 by Citizens JMP - Investing.com, accessed June 16, 2025, https://www.investing.com/news/analyst-ratings/nuvation-bio-price-target-maintained-at-6-by-citizens-jmp-93CH-4094609
66. US FDA approves Nuvation Bio's rare lung cancer drug - ET Pharma, accessed June 16, 2025, https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/fda-approves-ibtrozi-groundbreaking-treatment-for-rare-lung-cancer/121790569
67. Nuvation Bio's Ibtrozi FDA Approval: A Strategic Opportunity in ROS1-Positive NSCLC, accessed June 16, 2025, https://www.ainvest.com/news/nuvation-bio-ibtrozi-fda-approval-strategic-opportunity-ros1-positive-nsclc-2506/
68. FDA clears Nuvation lung cancer drug, setting up battle with Bristol Myers and Roche, accessed June 16, 2025, https://www.biopharmadive.com/news/nuvation-ibtrozi-fda-approval-ros1-lung-cancer/750499/
69. Nuvation Bio Gains FDA Approval for Ibtrozi to Compete with Pfizer, BMS, and Roche in Lung Cancer Market - Life Sciences Voice, accessed June 16, 2025, https://lifescivoice.com/nuvation-bio-gains-fda-approval-for-ibtrozi-to-compete-with-pfizer-bms-and-roche-in-lung-cancer-market/
70. Overall survival and central nervous system activity of crizotinib in ..., accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10937203/
71. Crizotinib as first line therapy for advanced ALK-positive non-small cell lung cancers - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4630528/
72. PROFILE 1014: lessons for the new era of lung cancer clinical research - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4630507/
73. Crizotinib Tops Chemo for ALK-Positive NSCLC With Brain Metastases - CancerNetwork, accessed June 16, 2025, https://www.cancernetwork.com/view/crizotinib-tops-chemo-alk-positive-nsclc-brain-metastases
74. Intracranial efficacy of crizotinib versus chemotherapy in PROFILE ..., accessed June 16, 2025, https://tcr.amegroups.org/article/view/9463/html
75. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer, accessed June 16, 2025, https://www.ctg.queensu.ca/docs/newinv/2015/Workshop6Reading_Profile1014.pdf
76. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/27022118/
77. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014 | Journal of Clinical Oncology - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.2015.63.5888
78. ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond - Hematology & Oncology - Millennium Medical Publishing, accessed June 16, 2025, https://www.hematologyandoncology.net/archives/july-2014/alk-inhibitors-in-non-small-cell-lung-cancer-crizotinib-and-beyond/
79. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases - PMC - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4451171/
80. New treatment options for crizotinib-resistant ALK-positive non-small cell lung cancer patients - AME Clinical Trials Review, accessed June 16, 2025, https://actr.amegroups.org/article/view/9037/html
81. Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/299471818_Intracranial_Efficacy_of_Crizotinib_Versus_Chemotherapy_in_Patients_With_Advanced_ALK-Positive_Non-Small-Cell_Lung_Cancer_Results_From_PROFILE_1014
82. ALK-Positive Lung Cancer - U.S. Pharmacist, accessed June 16, 2025, https://www.uspharmacist.com/article/alkpositive-lung-cancer
83. The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer, accessed June 16, 2025, https://www.mdpi.com/1424-8247/13/12/474
84. ascopubs.org, accessed June 16, 2025, https://ascopubs.org/doi/full/10.1200/JCO.2016.68.2497
85. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.20.03025
86. Entrectinib Meets Objective Response Rate End Point in ROS1+ NSCLC - CancerNetwork, accessed June 16, 2025, https://www.cancernetwork.com/view/entrectinib-meets-objective-response-rate-end-point-in-ros1-nsclc
87. FDA Approves Entrectinib for ROS1+ NSCLC and NTRK+ Solid Tumors, accessed June 16, 2025, https://www.targetedonc.com/view/fda-approves-entrectinib-for-ros1-nsclc-and-ntrk-solid-tumors
88. Lancet Oncology: Entrectinib effective, well-tolerated against ROS1 and NTRK lung cancers, especially with brain metastases - CU Anschutz newsroom, accessed June 16, 2025, https://news.cuanschutz.edu/cancer-center/entrectinib-effective-against-ros1-ntrk
89. Published Entrectinib Data Demonstrate Encouraging Responses in ROS1+ NSCLC, accessed June 16, 2025, https://www.onclive.com/view/published-entrectinib-data-demonstrate-encouraging-responses-in-ros1-nsclc
90. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/clincancerres/article/28/7/1302/682220/Updated-Integrated-Analysis-of-the-Efficacy-and
91. Press Releases | Sunday, Oct 21, 2018 - Genentech, accessed June 16, 2025, https://www.gene.com/media/press-releases/14759/2018-10-21/genentechs-investigational-personalized-
92. Roche's investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer, accessed June 16, 2025, https://www.roche.com/media/releases/med-cor-2018-09-24b
93. Entrectinib Shows Intracranial Response in NTRK+ Tumors and CNS Metastases - OncLive, accessed June 16, 2025, https://www.onclive.com/view/entrectinib-shows-intracranial-response-in-ntrk-tumors-and-cns-metastases
94. STARTRK: Phase I/II Study of Entrectinib in Children and Young Adults with Aggressive Solid or Brain Tumors | St. Jude Care & Treatment, accessed June 16, 2025, https://www.stjude.org/care-treatment/clinical-trials/startrk-solid-tumors-brain-tumors.html
95. Intracranial Responses Are Induced With Entrectinib in NTRK+ Tumors - Targeted Oncology, accessed June 16, 2025, https://www.targetedonc.com/view/intracranial-responses-are-induced-with-entrectinib-in-ntrk-tumors
96. Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001) - AACR Journals, accessed June 16, 2025, https://aacrjournals.org/cancerres/article/79/13_Supplement/CT131/637700/Abstract-CT131-Entrectinib-in-NTRK-fusion-positive
97. Entrectinib Improves Responses in NTRK Fusion-Positive Solid Tumors, accessed June 16, 2025, https://www.targetedonc.com/view/entrectinib-improves-responses-in-ntrk-fusionpositive-solid-tumors
98. Entrectinib Shows Activity in ROS1-Positive NSCLC - The ASCO Post, accessed June 16, 2025, https://ascopost.com/issues/october-25-2018/entrectinib-shows-activity-in-ros1-positive-nsclc/
99. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/31838007/
100. 476PUpdated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/336194958_476PUpdated_efficacy_and_safety_of_entrectinib_in_patients_with_NTRK_fusion-positive_tumors_Integrated_analysis_of_STARTRK-2_STARTRK-1_and_ALKA-372-001
101. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.20.03025
102. 543P Entrectinib in NTRK fusion-positive NSCLC: Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001 | Request PDF - ResearchGate, accessed June 16, 2025, https://www.researchgate.net/publication/345365982_543P_Entrectinib_in_NTRK_fusion-positive_NSCLC_Updated_integrated_analysis_of_STARTRK-2_STARTRK-1_and_ALKA-372-001
103. accessed January 1, 1970, https://www.nejm.org/doi/full/10.1056/NEJMoa1900991
104. accessed January 1, 1970, https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30696-1/fulltext
105. Taletrectinib vs Entrectinib in ROS1-Positive (ROS1+) Non-Small Cell Lung Cancer (NSCLC): A Matching-Adjusted Indirect Comparison (MAIC) - ISPOR, accessed June 16, 2025, https://www.ispor.org/heor-resources/presentations-database/presentation-cti/ispor-2025/poster-session-1/taletrectinib-vs-entrectinib-in-ros1-positive-ros1--non-small-cell-lung-cancer-nsclc--a-matching-adjusted-indirect-comparison-maic
106. Taletrectinib vs Entrectinib in ROS1-Positive Non-Small Cell Lung Cancer: A Matching-Adjusted Indirect Comparison - ISPOR, accessed June 16, 2025, https://www.ispor.org/docs/default-source/cti-meeting-21021-documents/9de28ee6-973a-42f1-b61e-7a3971ecfcac.pdf?sfvrsn=4b989225_0
107. Repotrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer - PMC, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11702311/
108. Repotrectinib Induces Durable Responses in ROS1+ NSCLC Subsets - OncLive, accessed June 16, 2025, https://www.onclive.com/view/repotrectinib-induces-durable-responses-in-ros1-nsclc-subsets
109. Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11473655/
110. Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC - Oncology Nursing News, accessed June 16, 2025, https://www.oncnursingnews.com/view/repotrectinib-showcases-early-intracranial-responses-in-select-ros1-nsclc
111. FDA Approves Repotrectinib for NTRK-Positive Locally Advanced, Metastatic Solid Tumors, accessed June 16, 2025, https://www.pharmacytimes.com/view/fda-approves-repotrectinib-for-ntrk-positive-locally-advanced-metastatic-solid-tumors
112. FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer - PMC - PubMed Central, accessed June 16, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11326972/
113. Repotrectinib Yields Enduring Responses in ROS1+ NSCLC - CancerNetwork, accessed June 16, 2025, https://www.cancernetwork.com/view/repotrectinib-yields-enduring-responses-in-ros1-nsclc
114. Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1. | Journal of Clinical Oncology - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9017
115. Efficacy | AUGTYRO™ (repotrectinib) for ROS1+ mNSCLC, accessed June 16, 2025, https://www.augtyrohcp.com/ros1/efficacy
116. Repotrectinib Shows Frontline Responses in ROS1+ Advanced NSCLC, accessed June 16, 2025, https://www.targetedonc.com/view/repotrectinib-shows-frontline-responses-in-ros1-advanced-nsclc
117. TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. - ASCO, accessed June 16, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT307911
118. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer - PubMed, accessed June 16, 2025, https://pubmed.ncbi.nlm.nih.gov/38197815/
119. Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer, accessed June 16, 2025, https://news.bms.com/news/details/2023/Updated-Data-from-TRIDENT-1-Trial-Show-Durable-Efficacy-Benefits-with-Repotrectinib-for-Patients-with-Locally-Advanced-or-Metastatic-ROS1-Positive-Non-Small-Cell-Lung-Cancer/default.aspx
120. Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions, accessed June 16, 2025, https://www.cancer.gov/news-events/cancer-currents-blog/2024/repotrectinib-lung-cancer-ros1
121. TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. | Journal of Clinical Oncology - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.TPS9637
122. TRIDENT-1 Update: Phase I/II Study of Repotrectinib in Patients With ROS1+ NSCLC | CCO, accessed June 16, 2025, https://clinicaloptions.com/activities/oncology/phase-iii-trident-1-update/18024-25668
123. Repotrectinib in ROS1 Fusion-Positive Non-Small Cell Lung Cancer - eScholarship.org, accessed June 16, 2025, https://escholarship.org/content/qt2ns0b4jk/qt2ns0b4jk_noSplash_6c47ed995232266907065ce52d06684d.pdf?t=sq2jft
124. Repotrectinib: a promising new therapy for advanced non-small cell lung cancer, accessed June 16, 2025, https://www.researchgate.net/publication/385555587_Repotrectinib_a_promising_new_therapy_for_advanced_non-small_cell_lung_cancer
125. APPLICATION NUMBER: - 218213Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review - accessdata.fda.gov, accessed June 16, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/218213Orig1s000MultidisciplineR.pdf
126. www.nejm.org, accessed June 16, 2025, https://www.nejm.org/doi/full/10.1056/NEJMoa2302299
127. Efficacy and Safety of Taletrectinib in Chinese Patients With ROS1+ Non–Small Cell Lung Cancer: The Phase II TRUST-I Study - ASCO Publications, accessed June 16, 2025, https://ascopubs.org/doi/10.1200/JCO.24.00731
128. FDA Accepts Ensartinib Application in Non-Small Cell Lung Cancer - Targeted Oncology, accessed June 16, 2025, https://www.targetedonc.com/view/fda-accepts-ensartinib-application-in-non-small-cell-lung-cancer